Search Results

Showing 10 from 25 results

Teva to Present Data Highlighting SD 809 at 20th International Congress of Parkinson s Disease and Movement Disorders

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Teva to Present Data from 18 Abstracts in Tardive Dyskinesia and Huntington Disease at the 21st International Congress of Parkinson s Disease and Movement Disorders

Facts Figures

Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top Line Data from the First Pivotal Study of Investigational Treatment for Patients with Tardive Dyskinesia

A Loved One s Perspective on Living with Tardive Dyskinesia

The emotional impact that a movement disorder like tardive dyskinesia TD can have on mental health can be very heavy

Teva to Present Data Highlighting Company s Pipeline in Neurological Disorders at 68th AAN Annual Meeting

What Teva Is Doing to Help Save the Lives of Thousands of Children with Cancer and Blood Disorders in Africa

Helping Address the Impact of Tardive Dyskinesia

Dr Richard Jackson Assistant Clinical Adjunct Professor University of Michigan School of Medicine Department of Psychiatry discusses the challenges both patients and doctors face when it comes to discussing the impact that tardive dyskinesia can have on patients lives which led to the creation of the IMPACT TD scale

Migraine at Work How it Impacts Us All

Following Teva s award of the Migraine Friendly Workplace Stamp we talk to team members at Teva about the experience of managing migraine at work and share their advice and coping strategies